Home urine C-peptide creatinine ratio (UCPCR) testing can identify type 2 and MODY in pediatric diabetes

Pediatric Diabetes

Volumn 14, Issue 3, 2013, Pages 181-188

  Besser, Rachel Ej ^a   Shields, Beverley M ^a   Hammersley, Suzanne E ^a   Colclough, Kevin ^b   Mcdonald, Timothy J ^a,b   Gray, Zoe ^c   Heywood, James Jn ^d   Barrett, Timothy G ^e   Hattersley, Andrew T ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

^c BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

C peptide; Child; Classification; Diabetes mellitus

Indexed keywords

C PEPTIDE; CREATININE;

ADOLESCENT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; URINE C PEPTIDE CREATININE RATIO;

ADOLESCENT; ALGORITHMS; C-PEPTIDE; CHILD; COHORT STUDIES; CREATININE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; DOWN-REGULATION; FAMILY; FEMALE; GREAT BRITAIN; HUMANS; MALE; OUTPATIENT CLINICS, HOSPITAL; POSTPRANDIAL PERIOD; SELF CARE; SENSITIVITY AND SPECIFICITY;

EID: 84876809846     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12008     Document Type: Article

References (32)

1. Hattersley A, Bruining J, Shield J, Njolstad P, Donaghue K. ISPAD Clinical Practice Consensus Guidelines 2006-2007. The diagnosis and management of monogenic diabetes in children. Pediatr Diabetes 2006: 7: 352-360.
2. Craig ME, Hattersley A, Donaghue KC. Definition, epidemiology and classification of diabetes in children and adolescents. Pediatr Diabetes 2009: 10 (Suppl. 12): 3-12.
3. Schober E, Rami B, Grabert M et al. Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with Type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database. Diabet Med 2009: 26: 466-473.
4. Zeitler P. Update on nonautoimmune diabetes in children. J Clin Endocrinol Metab 2009: 94: 2215-2220.
5. Deckelbaum RJ, Williams CL. Childhood obesity: the health issue. Obes Res 2001: 9 (Suppl. 4): 239S-243S.
6. Shields BM, McDonald TJ, Ellard S, Campbell MJ, Hyde C, Hattersley AT. The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. Diabetologia 2012: 55: 1265-1272.
7. Ludvigsson J, Carlsson A, Forsander G et al. C-peptide in the classification of diabetes in children and adolescents. Pediatr Diabetes 2011: 13: 45-50.
8. Dahlquist G, Blom L, Holmgren G et al. The epidemiology of diabetes in Swedish children 0-14years--a six-year prospective study. Diabetologia 1985: 28: 802-808.
9. Copeland KC, Zeitler P, Geffner M et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab 2011: 96: 159-167.
10. Haines L, Wan KC, Lynn R, Barrett TG, Shield JP. Rising incidence of type 2 diabetes in children in the U.K. Diabetes Care 2007: 30: 1097-1101.
11. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002: 25: 89-94.
12. Flint A, Arslanian S. Treatment of type 2 diabetes in youth. Diabetes Care 2011: 34 (Suppl. 2): S177-S183.
13. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 2011: 53: 2504-2508.
14. Berger B, Stenstrom G, Sundkvist G. Random C-peptide in the classification of diabetes. Scand J Clin Lab Invest 2000: 60: 687-693.
15. ADA. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012: 34 (Suppl. 1): S62-S69.
16. Couper J, Donaghue KC. Phases of diabetes in children and adolescents. Pediatr Diabetes 2009: 10 (Suppl. 12): 13-16.
17. Besser RE, Shepherd MH, McDonald TJ et al. Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes. Diabetes Care 2011: 34: 286-291.
18. Tfayli H, Bacha F, Gungor N, Arslanian S. Phenotypic type 2 diabetes in obese youth: insulin sensitivity and secretion in islet cell antibody-negative versus -positive patients. Diabetes 2009: 58: 738-744.
19. Greenbaum CJ, Mandrup-Poulsen T, McGee PF et al. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008: 31: 1966-1971.
20. McDonald TJ, Knight BA, Shields BM, Bowman P, Salzmann MB, Hattersley AT. Stability and reproducibility of a single-sample urinary C-peptide/creatinine ratio and its correlation with 24-h urinary C-peptide. Clin Chem 2009: 55: 2035-2039.
21. Besser RE, Ludvigsson J, Jones AG et al. Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care 2011: 34: 607-609.
22. Jones AG, Besser REJ, McDonald TJ et al. Urine C-peptide creatinine ratio is an alternative to stimulated serum C-peptide measurement in late onset, insulin-treated diabetes. Diabet Med 2011: 28: 1034-1038.
23. Palmer JP, Fleming GA, Greenbaum CJ et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004: 53: 250-264.
24. The DCCT Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987: 65: 30-36.
25. Ludvigsson J, Heding LG, Larsson Y, Leander E. C-peptide in juvenile diabetics beyond the postinitial remission period. Relation to clinical manifestations at onset of diabetes, remission and diabetic control. Acta Paediatr Scand 1977: 66: 177-184.
26. Katz LE, Jawad AF, Ganesh J, Abraham M, Murphy K, Lipman TH. Fasting c-peptide and insulin-like growth factor-binding protein-1 levels help to distinguish childhood type 1 and type 2 diabetes at diagnosis. Pediatr Diabetes 2007: 8: 53-59.
27. Tung YC, Lee JS, Tsai WY, Hsiao PH. Evaluation of beta-cell function in diabetic Taiwanese children using a 6-min glucagon test. Eur J Pediatr 2008: 167: 801-805.
28. Rolla AR, Rakel RE. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues. Clin Ther 2005: 27: 1113-1125.
29. O'Rahilly SP, Matthews DR, Hosker JP, Turner RC. Metabolic abnormalities in children of non-insulin dependent diabetics. Br Med J (Clin Res Ed) 1986: 293: 1437-1438.
30. McDonald TJ, Colclough K, Brown R et al. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes. Diabet Med 2009: 55: 2035-2039.
31. Borg H, Marcus C, Sjoblad S, Fernlund P, Sundkvist G. Islet cell antibody frequency differs from that of glutamic acid decarboxylase antibodies/IA2 antibodies after diagnosis of diabetes. Acta Paediatr 2000: 89: 46-51.
32. Bowman P, McDonald TJ, Shields BM, Knight BA, Hattersley AT. Validation of a single-sample urinary C-peptide creatinine ratio as a reproducible alternative to serum C-peptide in patients with Type 2 diabetes. Diabet Med 2012: 29: 90-93.